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Abstract: Despite tremendous progress in medicine during last couple of decades, cancer still 
remains the most horrifying diagnosis for anybody due to its almost inevitable futility. According 
to American Cancer Society Statistics, it is estimated that only in the United States more than 
half a million people will die from cancer in 2006. For those who survive, probably the most 
fearsome symptom regardless of cancer type will be the pain. Although most pain specialists 
and oncologists worldwide are well aware of the importance to adequately treat the pain, it was 
yet established that more than half of cancer patients have insufﬁ  cient pain control, and about 
quarter of them actually die in pain. Therefore, in this review article we attempted to provide 
the comprehensive information about different options available nowadays for treating cancer 
pain focusing on most widely used pharmacologic agents, surgical modalities for intractable 
pain control, their potential for adverse effects, and ways to increase the effectiveness of treat-
ment maximally optimizing analgesic regimen and improving compliance.
Keywords: analgesic ladder, opioids, adjuvant, neuromodulation
General consideration in cancer pain management
Despite all advances in prevention, early detection, and newer, more effective treat-
ment modalities, cancer in general remains one of the most debilitating and deadly 
diseases nowadays, and is the second leading cause of mortality of all Americans 
(Jemal et al 2004). The sheer potential for suffering from cancer can be a horrifying 
experience for anyone bearing this diagnosis, while pain is probably one of the most 
frightening of all cancer symptoms for patients and their families (Valdimarsdottir et al 
2002; Winslow et al 2005). According to statistics published by the American Cancer 
Society in 2002, “50%–70% of people with cancer experience some degree of pain” 
(ACS 2002), which usually only intensiﬁ  es as the disease progresses. Less than half 
get adequate relief of their pain, which negatively impacts their quality of life. The 
incidence of pain in advanced stages of invasive cancer approaches 80% and it is 90% 
in patients with metastases to osseous structures (Pharo and Zhou 2005). 
Suboptimal pain control can be very debilitating. Patients and their families tend to 
be under great distress after the diagnosis of cancer. Although many of these patients 
carry a very poor prognosis, prompt and effective pain control can prevent needless 
suffering, may signiﬁ  cantly improve the quality of their lives, and may potentially spare 
families the feeling of helplessness and despair. Although cancer can be a terminal 
disease, there should be no reason to deny a patient the opportunity to live productively 
and free of pain. Severe pain can interfere with physical rehabilitation, mobility, and 
proper nutrition. A signiﬁ  cant number of cancer patients are subsequently diagnosed 
with depression. Therefore, the goals of pain control in any patient with cancer should 
be to optimize the patient’s comfort and function while avoiding unnecessary adverse 
effects from medications (Cherny 2000).Therapeutics and Clinical Risk Management 2007:3(3) 382
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Several practice guidelines exist for the treatment of 
cancer pain (Jacox et al 1994; Wilson et al 1997; Benedetti 
et al 2000; Panchal et al 2005). From these, probably the 
most widely used are the guidelines developed by the 
World Health Organization (WHO) 20 years ago, which 
include the 3-step “analgesic ladder” designed to facilitate 
and standardize pharmacologic cancer pain management 
and advise physicians worldwide how to better provide 
pain management to their patients (Figure 1). According 
to the ladder algorithm, selection of nonopioid, opioid, 
and adjuvant analgesic therapy should be individualized, 
as directed by the intensity of the pain. This approach 
has been shown to provide good to satisfactory pain re-
lief over a 10-year observation period in 88% of cancer 
patients in an over-2000-patient anesthesiology-based 
pain service (Zech et al 1995). On the other hand, it was 
estimated in 1994 that less than half of cancer patients in 
general practice get adequate relief of their pain, and 25% 
actually die in pain (Jacox et al 1994). This is particularly 
disappointing because the pain endured by 90% of these 
patients could have been well managed with relatively 
simple interventions (Friedman and Rodgers 2004). 
With ongoing progress in the pain management ﬁ  eld, a 
number of palliative care specialists argue that the WHO 
program, even though updated in 1990, had not kept pace 
with the rapidly changing developments in oncology and 
pain research (Meldrum 2005). It was reported that the cur-
rent ladder method consistently failed to provide sufﬁ  cient 
relief to 10%–20% of advanced cancer patients with pain, 
particularly in cases of neuropathic pain and pain associ-
ated with bone involvement (Ahmedzai 1997). Therefore, 
it was suggested that a fourth, “interventional”, step be 
added to the 3-step WHO analgesic ladder once opioids 
and other drugs fail, which will incorporate nerve blocks, 
intrathecal drug delivery systems, and other surgical inter-
ventions (Miguel 2000). However, it may be reasonable to 
further adjust the WHO pain management ladder from its 
current approach to a more sophisticated 5-step algorithm 
that would separate potentially reversible neuromodula-
tion (electrical or chemical) from virtually irreparable 
destructive procedures, such as cordotomy, rhizotomy, or 
thalamotomy, and would also include physical and psycho-
logical modalities at every step along the entire continuum 
of care (Figure 2).
There are many challenges that physicians may en-
counter in the treatment of cancer pain. Generally, pain 
is a subjective feeling that has not to date been easily and 
universally quantified (Noble et al 2005). Patients with 
similar cancer types may experience different intensities 
of pain, may respond to the same analgesic in different 
ways, and may exhibit varying sensitivities to the adverse 
effects from many of the drugs used. Because cancer pain 
is usually multifaceted, a single analgesic may not be 
sufficient enough to alleviate all the aspects of pain that 
the patient is experiencing, thus complicating the phar-
macological regimen. Depending on the type and extent 
of the cancer, the administration routes may be limited 
for some patients and more innovative methods of drug 
delivery may need to be utilized. Society has also placed 
limitations on adequate pain control because of some un-
founded concerns, including fear of physical dependency 
and addiction to opioids, as well as discomforting side 
effects that may occur with long-term analgesic treatment 
(Bloodworth 2005). Although important in considering 
opioid regimen in patients with nonmalignant chronic 
pain (Nedeljkovic et al 2002), it has been highlighted, 
however, that neither physical dependency nor addiction 
are significant problems in the management of cancer 
patients (Portenoy 1996). 
Another challenge to the treatment of cancer pain 
is the paucity of good clinical trials providing objec-
tive data that can be extrapolated to individual patients. 
Some of the limitations with the clinical trials found in 
the literature today include the heterogeneity of cancer 
pain types, the limited number of patients enrolled, the 
spectrum of available analgesics and doses used for 
optimal pain control, the lack of a single objective pain 
scale, and the variable duration of treatment provided 
in different textbooks or guidelines. In addition, inad-
equate pain assessment, lack of knowledge about modern 
modalities for chronic pain management, and fear of 
potential liability and censure by regulatory agencies for 
prescribing opioids among physicians in general practice 
may play another role in undertreating the cancer pain 
(McCarberg and Barkin 2001; NCCN 2005). 
Initial assessment of cancer pain
Comprehensive pain assessment is one of the most im-
portant initial steps for successful management of cancer 
pain. It is recommended that pain should be evaluated at 
every clinical visit and incorporated as the “fifth vital 
sign” (Benedetti et al 2000). Ideally, the assessment 
should target the severity, duration, quality, and location 
of the pain (Turk et al 2002). Reports of pain made by the 
patient should be the primary source of pain assessment 
and should be obtained at periodic intervals. Periodic Therapeutics and Clinical Risk Management 2007:3(3) 383
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monitoring may include, but is not limited to a patient’s 
verbal report of treatment efficacy and any side effects 
associated with pain management. Analyses of aggregated 
outcomes are essential to continuous quality improvement 
of chronic pain management in the clinical setting (Wilson 
et al 1997). In addition, it is important for the clinician 
to inquire about how the pain has affected patient’s daily 
activities and relationships with others.
To help introduce objectivity in the evaluation, a 
number of pain scales have been utilized to quantify pain 
intensity. Currently, it is recommended that pain should 
be measured using a numerical rating scales (from 0–10, 
where 0 indicating no pain and a 10 indicating the worst 
imaginable pain) (Benedetti et al 2000). In cases of chil-
dren, the elderly, and patients with language differences, 
facial expression scales, ie, Wong-Baker scale, should 
be considered (Wong and Baker 1988). This enables 
clinicians to make a continuous objective assessment of 
pain intensity throughout the course of the treatment. To 
assess the quality of the painful stimulus, it is best to al-
low the patients to describe the pain themselves, which 
very often helps healthcare practitioners get a better 
understanding of the source and the type of pain. Clini-
cians should attempt to obtain more information about 
the pain by conducting pain histories to determine a cause 
and the best treatment modality (Benedetti et al 2000). It 
has also been suggested that clinicians pay more attention 
to psychological factors because fear and anxiety may 
have significant effect on the perception and experience 
of pain (Turk et al 2002).
There are two types of pain: nociceptive pain and 
neuropathic pain. Nociceptive pain stimulus is transmit-
ted by peripheral nerves from specialized pain recep-
tors, called nociceptors, whose function is to report any 
injury, which in cancer patients is usually secondary to 
invasion of tumor into bone, joints, or connective tissue. 
Nociceptive pain can be somatic (usually sharp or dull 
well-localized aching or squeezing sensation), visceral 
(usually poor-localized deep pressure-like sensation), and 
associated with invasive procedures, ie, lumbar puncture, 
biopsy, surgical intervention. Neuropathic pain, on the 
other hand, results from mechanical or metabolic injury to 
the nervous system itself, either centrally or peripherally, 
and is generally associated with mishandling of incoming 
somatosensory stimuli. In patients with advanced cancer 
this can be a result of tumor infiltration of nerves or 
nerve roots, as well as iatrogenic in nature as a result of 
exposure to chemotherapeutic agents (ie, vinca alkaloids) 
or radiation therapy. 
In general, nociceptive pain responds relatively 
well to traditional analgesics, including nonsteroidal 
anti-inflammatory drugs (NSAIDs) and opioids, whereas 
neuropathic pain remains more difficult to treat, and more 
commonly is better alleviated by antiepileptic drugs or 
Figure 1 The World Health Organization cancer pain treatment step ladder.
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Figure 2 Modiﬁ  ed analgesic ladder for the treatment of cancer pain.
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tricyclic antidepressant agents, which modulate action 
potential propagation and the availability of chemical 
neurotransmitters such as norepinephrine and serotonin. 
It is important to keep in mind that cancer patients will 
generally experience a combination of pain types, and the 
treatment of the disease, ie, surgery, radiation, chemo-
therapy, may be an important source of the painful stimuli 
along with progression of the disease itself. 
Pharmacological management 
of cancer pain
According to WHO cancer pain treatment ladder the initial 
step in any pain management is consisted of using nonopioid 
analgesics, which include acetaminophen, aspirin, NSAIDs, 
such as ibuprofen or ketorolac, and the most recent addition, the 
selective cyclooxygenase type 2 (COX-2) inhibitors, such as ro-
fecoxib, celecoxib and valdecoxib. Most nonopioid analgesics 
used for cancer pain treatment are summarized in Table 1.
Acetaminophen (paracetamol) is recommended as a 
ﬁ  rst step analgesic for mild to moderate pain. Although its 
mechanism of action is not fully understood, it is thought to 
inhibit central prostaglandin synthesis in the central nervous 
system, which explains its analgesic and antipyretic activity 
without any effects on inﬂ  ammation. Acetaminophen is not 
generally used alone for cancer pain, but rather in combina-
tion with opioids (ie, hydrocodone, codeine, etc) Although 
acetaminophen is effective and well tolerated by most of 
the patients, its use is limited by a maximum daily dose 
of 4000 mg (2000 mg/day in patients with hepatic dysfunc-
tion) due to potential hepatic toxicity. On the other hand, 
the gastro-intestinal toxicities seen with chronic NSAIDs 
use are not seen with acetaminophen. Acetaminophen is 
excreted by kidneys and dosing must be adjusted in patients 
with signiﬁ  cant renal insufﬁ  ciency.
Aspirin is another drug from this group that can be used 
for mild to moderate pain control. Unlike acetaminophen, 
aspirin serves not only as an analgesic and antipyretic but 
also as an anti-inﬂ  ammatory agent, which may be an impor-
tant addition to the therapeutic effect in patients who have 
severe inﬂ  ammatory pain. It is a safe over-the-counter drug 
widely used for noncancerous acute pain control and for 
management and prophylaxis of myocardial infarction due 
to its well-established anti-platelet action. However, it has to 
be used very cautiously in cancer patients, as in high doses 
required for adequate pain control (650–1000 mg orally ev-
ery 4–6 hours) aspirin can cause a number of unwanted side 
effects, such as tinnitus, vertigo, hyperventilation, as well 
as increased risk of peptic ulcer disease and gastrointestinal 
(GI) bleedings. If overdosed, aspirin can cause cardiovascular 
instability, exacerbate underlying renal insufﬁ  ciency, and 
even lead to coma with renal failure, metabolic acidosis, 
and respiratory arrest.
NSAIDs are potent analgesics, antipyretics, and anti-
inﬂ  ammatory agents, which makes them useful for cancer 
related pain of musculoskeletal origin. They work through 
nonspeciﬁ  c inhibition of cyclooxygenase (COX), an enzyme 
that mediates prostaglandin synthesis from arachidonic acid. 
Because of nonspeciﬁ  c inhibition of both isoenzymes of cy-
clooxygenase (COX-1 and COX-2), all nonselective NSAIDs 
have signiﬁ  cant adverse effects on gastric mucosa and renal 
parenchyma, and some inhibit platelet function. With chronic 
use, they can cause serious gastric ulcerations and bleeding, 
which is a result of the inhibition of COX-1 isoenzyme. 
Therefore, NSAIDs may not be an optimal choice in patients 
who are experiencing nausea and vomiting associated with 
receiving chemotherapy or who have a history of GI bleeding 
in the past. In addition, care must be taken in patients that 
may already have renal insufﬁ  ciency related to advanced age 
or disease progression because of the potential to exacerbate 
these conditions due to modulation of prostaglandin activity 
on renal blood ﬂ  ow (Dunn 1984). The NSAIDs have maxi-
mum daily doses that limit their utility in moderate to severe 
cancer pain management. All of the NSAIDs are available 
orally, but only ketorolac is available in parenteral form for 
pain control. Indomethacin, like aspirin, is available in sup-
pository forms for rectal administration.
COX-2 inhibitors (rofecoxib, celecoxib, and valdecoxib) 
have less potential for GI and hematological side effects seen 
with the traditional NSAIDs, a factor that makes them more 
attractive for cancer pain management. These drugs speciﬁ  -
cally inhibit the COX-2 isoenzyme, which is considered the 
inducible isoenzyme during painful stimuli. This selectivity 
spares the inhibition of COX-1, which is thought to be consti-
tutive in the GI tract and required for normal gastrointestinal 
function. In addition, there are emerging studies that show 
an antitumoral effect with these agents due to inhibition of 
cytokine production seen in many solid tumors (Rouff and 
Lema 2003). This class of drugs is an attractive option in 
those patients with cancer involving inﬂ  ammation and those 
who are at high risk for GI bleeding or platelet dysfunction. 
COX-2 inhibitors may also be considered as one of the most 
effective agents for patients with bone metastasis as prosta-
glandins appear to play an important role in pathogenesis of 
bone pain (Haegerstam 2001). In addition smaller doses of 
opioids can be used with COX-2 inhibitors thereby minimiz-
ing potential risk for opioid side effects. Because of their Therapeutics and Clinical Risk Management 2007:3(3) 386
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Table 1 Most commonly used nonopioid analgesics in United States
Drug Preparation  Dose  Maximum  Comments
Acetaminophen  tablets – 325, 500, 650 mg  325–1000 mg PO  4000 mg/day  No anti-inﬂ  ammatory 
  suspension – 160, 325 mg/5 ml  q4–6h PRN    effect. Hepatotoxic if 
  suppository – 80, 120, 125, 200,       overdosed
  300, 325, 600, 650 mg 
Aspirin  tablets – 81, 162, 325, 500, 650, 975 mg  325–650 mg PO  4000 mg/day  Bleeding risk is the most
  suppository – 60, 120, 200, 300, 600 mg  q4h PRN    signiﬁ  cant concern
Diclofenac  tablets – 50 mg  50 mg PO  150 mg/day  Alt dose for SR form
  delayed-release – 25, 50, 75, 100 mg SR  BID-TID    is 100 mg PO daily
Etodolac  tablets – 400, 500 mg  200–400 mg PO  1200 mg/day  The dose for SR is
  extended-release – 400, 500, 600 mg SR  q6–8h    400–1000 mg once daily
  capsules – 200, 300 mg
Ibuprofen  tablets – 100, 200, 400, 600, 800 mg  400–600 mg PO   3200 mg/day  Use with caution in patients
  suspension – 40 mg/ml, 100 mg/5 ml  q4–6h PRN    with history of peptic ulcer
Indomethacin  capsules – 25, 50 mg  25–50 mg PO  200 mg/day  Use with caution in patients
  extended-release – 75 mg SR  TID    with history of peptic ulcer
  suspension – 25 mg/5 ml
  suppository – 50 mg
Ketoprofen  tablets – 12.5 mg  25–50 mg   300 mg/day  Maximum dose for SR
  capsules – 25, 50, 75 mg  PO q6h–q8h    form is 200 mg/day
  extended-release – 100, 150, 200 mg SR 
Ketorolac  tablets – 10 mg  10 mg PO  40 mg/day PO or  IV therapy should not
  parenteral – 15 mg/ml, 30 mg/ml  q4–6h PRN or  120 mg/day IV/IM  exceed 5 days
    30 mg IV/IM q6h 
Meclofenamate  capsules – 50, 100 mg  50–100 mg PO   400 mg/day
    q4–6h PRN    
Mefenamic acid  capsules – 250 mg  250 mg PO   For therapy ≤ Recommended  ﬁ  rst
    q4–6 PRN  1 wk in duration  dose is 500 mg PO
Meloxicam  tablets – 7.5, 15 mg  7.5–15 mg PO  15 mg/day  COX-2 preferential
  suspension – 7.5 mg/5 mL  once daily    NSAID
Nabumetone  tablets – 500, 750 mg  100–2000 mg once daily    May divide daily dose to BID
 2000  mg/day
Naproxen  tablets – 250, 375, 500 mg  250–500 mg PO BID  1500 mg/day   Maintenance dose is
  SR – 375, 500 mg    for 3–5days  maximum 1000 mg/d for 6  
  suspension – 125 mg/5 ml      months
Oxaprozin  tablets – 600mg  1200 mg PO  
    once daily  1800 mg/day 
Piroxicam  capsules – 10, 20 mg  20 mg PO   20 mg/day  May divide daily dose BID
   once  daily
Sulindac  tablets – 150, 200 mg  150–200 mg PO BID  400 mg/day 
Tolmetin  capsules – 400 mg  200–600 mg PO   1800 mg/day 
  tablets – 200, 600 mg  BID-TID   
Tramadol  tablets – 50 mg  50–100 mg PO   400 mg/day  Maximum dose for SR
  extended-release – 100, 200, 300 mg SR  q4–6h PRN; 100–    form is 300 mg/day
    300 mg QD for SR
Celecoxib  capsules – 100, 200, 400 mg  200 mg PO BID  400 mg/day  COX-2 inhibitor
Rofecoxib*  tablets – 12.5, 25, 50 mg  50 mg PO daily for 5  Withdrawn from the market in 2004 
  suspension – 12.5 mg/5 ml,   days, then 25 mg PO
    25 mg/5 ml daily 
Valdecoxib*  tablets – 10, 20 mg  10-20 mg PO BID  Withdrawn from the market in 2005
Abbreviations: PO, oral; IM, intramuscular; IV, intravenous; PRN, as needed; BID, twice daily; TID, three times daily; NSAID, nonsteroidal anti-inﬂ  ammatory drug; 
SR, sustained release.
Note: *COX-2 inhibitors Rofecoxib (Vioxx) and Valdecoxib (Bextra) were removed from the market due to increased cardiovascular and dermatological risks.Therapeutics and Clinical Risk Management 2007:3(3) 387
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relatively short half-lives, they are also capable of treating 
breakthrough pain. 
However, like NSAIDs, COX-2 inhibitors should be 
used with caution with those at risk for renal failure, and 
case reports have emerged documenting this severe adverse 
effect (Morales and Mucksavage 2002). Moreover, the 
overall safety of COX-2 inhibitors, particularly rofecoxib, 
has recently come into question due to increased risk of 
acute myocardial infarction and sudden cardiac death 
among high-dose chronic users of this drug (Bombardier 
et al 2000; Mukherjee et al 2001), which led to voluntarily 
withdrawal of rofecoxib (Vioxx®) from the U.S. market in 
2004 (Merck 2004; Singh 2004). On the other hand, our 
experience shows that the majority of patients with dis-
seminated metastatic bone disease will accept the risk of 
having a heart attack while on COX-2 inhibitors as opposed 
Table 2 Most commonly used opioid analgesics in United States
Drug name  Formulation  Duration of   Recommended 
    action (hours)  analgesic dose
Morphine sulfate  Tablets (IR): 15 and 30 mg  2–4  10–30 mg q3–4h 
  Rectal suppositories: 5, 10, 20, and 30 mg    10–20 mg q4h
  Parenteral (SC, IM, IV): 2, 4 and 20 mg/ml    2.5–10 mg q2–6h1
  Epidural    3–5 mg once, then 0.1–0.7 mg/hr
  Intrathecal    Start 100:1 IT-to-IV, then titrate to pain
MS Contin®  Tablets (CR): 15, 30, 60, 100, 200 mg  8–12  15–30 mg q8–12h
Oramorph® SR  Tablets (SR): 15, 30, 60, 100 mg  8–12  15–30 mg q8–12h
Kadian®  Capsules (ER): 20, 30, 50, 60, 100 mg  24  20 mg q24h, may increase by 20 mg
      increments every other day
Avinza®  Capsules (ER): 30, 60, 90, 120 mg  24  30 mg q24h, may increase by 30 mg
      increments q4days (max 1600 mg/d)
Codeine  Tablets: 15, 30, 60 mg  2–4  15–60 mg q4–6h (max 60 mg/d)
  Oral solution: 15 mg/5 ml, 30 mg/5 ml
Dilaudid® (hydromorphone)  Tablets (IR): 2, 4, 8 mg; Oral solution:   2–4  2–8 mg q3-4h for PO and PR
  5 mg/5 mL; Suppositories: 3 mg    
  Parenteral (SC, IM, IV): 1, 2, 4, 8 mg/ml;     1–4 mg q4–6h2
  Intrathecal    Start 100:1 IT-to-IV, then titrate to pain
Palladone®  Capsules (ER): 12, 16, 24, 32 mg  24  Withdrawn from the market in 2005
Roxycodone® (oxycodone) Tablets  (IR3): 5, 15, 30 mg, capsules: 5 mg;   2–4  5–30 mg q4h
  Oral solution: 5 mg/5 ml, 20 mg/ml
OxyContin®  Tablets (SR): 10, 20, 40, 80, 160 mg  12  10–160 mg q12h4
Opana® (oxymorphone)  Tablets (IR) 5, 10 mg  4-8  5–10 mg q4–6h
Opana®ER  Tablets (ER) 5, 10, 20, 40 mg  12  5–40 mg q12h
Propoxyphene HCl  Capsules: 65 mg5  2–4  65 mg q4h (max 390 mg/24h)
Methadone  Oral solution: 5 mg/5 ml, 10 mg/5 ml,   4–8  2.5–10 mg q3-6h
  10 mg/ml; Tablets: 5, 10, 40 mg    Has very long half-life (8–60 hours)
Meperidine (Demerol®)  Oral solution: 50 mg/5 ml  2–4  50–150 mg q3–4h (decrease dose if given  
  Tablets: 50, 100 mg    IV, administer slow or via PCA).
  Parenteral (SC,IM,IV): 10 mg/ml    Not recommended for chronic use.
Fentanyl  Parenteral (IM,IV)  1–3  25–100 mcg q1–2h 
      0.5–1.5 mcg/kg/hr IV infusion via PCA
Actiq®  Oral transmucosal lozenge: 200, 400, 600,  2–4  Start with 200 mcg for breakthrough
  800, 1200, 1600 mcg    pain episodes6, then titrate to pain 
Duragesic®  Transdermal patch: 25, 50, 75, 100 mcg/hr  72  25 mcg/h q72hr, may increase q3–6days
Abbreviations: IR, immediate release; CR, controlled release; SR, sustained release; ER, extended release.
Notes:  1Alternative dose for IV morphine: 0.1 mg/kg IV once, then 1-10mg/hr via IV PCA.
2 Start 0.2-0.6 mg q2-3h (IV), 0.8-1 mg q4-6h (SC/IM) in opiate-naive patients
3 Oxycodone is also available as OxyIR (5 mg immediate release tablets); doses are similar to Roxycodone
4 80 mg and 160 mg formulations of Oxycontin should be used in opiate-tolerant patients only
5 65 mg propoxyphene hydrochloride (Darvon®) = 100 mg propoxyphene napsylate (Darvon-N)
6 Can be also used IM or SC at 2.5-10 mg q8-12h, but generally PO is recommended for chronic pain
7 For use only in opiate tolerant patients, recommended maximum dose is 4 units per dayTherapeutics and Clinical Risk Management 2007:3(3) 388
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to living with unbearable pain or experiencing severe side 
effects from high-dose opioid therapy. Therefore, COX-2 
inhibitors may still serve as a good option for relief of 
musculoskeletal pain in patients with terminal cancer. No 
parenteral forms of COX-2 inhibitors are commercially 
available at present in the Uniteds States.
Tramadol is a centrally acting nonopiate analgesic 
with low affinity for µ-opioid receptors, and is effective 
in the treatment of moderate to severe pain. It has been 
also shown to inhibit reuptake of serotonin and norepi-
nephrine, which synergistically enhances its weak opi-
oid mechanism of action (Raffa et al 1992; Desmeules 
et al 1996). This may explain the reduced incidences of 
abuse, respiratory depression and other adverse effects 
of traditional opioids in patients on long-term tramadol 
therapy (Raffa 2001). Tramadol can be beneficial in pa-
tients who fail nonopioid therapy and wish to delay taking 
opioids avoiding the common side effects of constipation, 
somnolence, and fatigue. It is shown to be effective in 
such nonmalignant opioid-resistant chronic pain states 
as fibromyalgia and diabetic neuropathy (Harati et al 
1998; Russell et al 2000), and had marginal to moderate 
success in the treatment of chronic cancer pain (Grond 
et al 1999). Unlike the NSAIDs, tramadol has no anti-
inflammatory activity, extensively metabolized in the 
liver and is available in tablet form only.
As pain progresses, nonopioid regimens alone may 
not be sufﬁ  cient to provide necessary analgesia or may be 
approaching maximum recommended daily doses. At this 
point, a trial of opioid and nonopioid analgesic combina-
tion may be instituted. A variety of ﬁ  xed combinations 
with acetaminophen are available on the market, which 
usually include codeine, hydrocodone, oxycodone, or pro-
poxyphene (Raffa 2001). Based on extensive evidence of 
their efﬁ  cacy, these combinations are recommended in the 
second step of WHO analgesic ladder for the management 
of moderate to severe pain (Schug et al 1990). Another 
attractive choice for long-term pain treatment is the com-
bination of acetaminophen with tramadol, which has been 
demonstrated in humans to be more effective with a faster 
onset and longer duration of action than either component 
alone, without increasing the incidence of adverse events 
(Raffa 2001). Nevertheless, this phase requires frequent 
and constant evaluation of the patient to titrate each drug 
to a successful dose, which is in general limited by the 
nonopioid component. Once the limit is reached for these 
agents (eg, >4 g/day of acetaminophen), the next step is to 
advance to pure opioid therapy.
The opioids are typically the most common drug 
class used in the treatment of cancer pain. They work by 
binding to µ-opioid receptors within the central nervous 
system, which are responsible for opioid-mediated an-
algesia, respiratory depression, sedation, physiological 
dependence, and tolerance (Gutstein and Akil 2001). 
Analgesic effect of opioids is largely dependent on µ-re-
ceptor saturation and is thus influenced by the type and 
severity of the pain, prior exposure to opioids, and indi-
vidual distribution of receptors (Friedman and Rodgers 
2004). There is no maximum dose for these agents; they 
are only limited by the development of side effects that 
are patient specific in their onset and severity. Common 
opioid side effects include nausea, constipation, sedation, 
and confusion, and they can be often managed without 
compromising pain control by adjusting the daily dose 
of the drug or in persistent cases by instituting additional 
medications, such as metoclopramide for nausea, laxa-
tives for constipation, or methylphenidate for sedation.
Prolonged use of opioids may lead to development of 
tolerance (the need to increase opioid dose with time to 
maintain equipotent analgesic effects) and opioid-induced 
abnormal hypersensitivity to pain (so-called pro-nociceptive 
sensitization). Experimental studies suggest that both phe-
nomena could be related to N-methyl-D-aspartate (NMDA) 
receptor mediated changes in central nervous system (Trujillo 
and Akil 1991; Mao et al 1994, 1995; Alvarez et al 2001). 
Opioid desensitization and hypersensitization of NMDA 
receptors from prolonged opioid therapy may both contribute 
to an apparent decrease in analgesic efﬁ  cacy, regardless of 
the progression of the pain. Thus, in some instances, treating 
increasing pain with increasing doses of same opioid may 
be futile (Ballantyne and Mao 2003). Although this has not 
been shown conclusively in the clinical setting, NMDA re-
ceptor antagonists (ketamine, dextromethorphan, memantine, 
amantadine) and low-dose opioid antagonists (naloxone, 
naltrexone) might partially reverse opioid tolerance. In ad-
dition, because the cross-tolerance to opioids is incomplete, 
opioid rotation (switching from one opioid to another) can 
be also used to overcome the unwanted adverse effects of 
opioid receptor desensitization (Mercadante 1999a; Lussier 
and Pappagallo 2004). 
Exogenous opioids may also affect hormonal and immune 
systems with prolonged use, leading to reduced fertility, 
libido, and drive, along with moderate immunosuppression 
(Finch et al 2000; Ballantyne and Mao 2003). However, in 
cases of chronic cancer pain these adverse effects of opioid 
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tion, may be considered as not very important, and should 
not prevent the physician from providing adequate pain 
control to the patient.
A wide variety of opioids are currently available in the 
market (Table 2), and are roughly categorized into controlled 
(or sustained) release (SR), such as MS Contin®, Avinza®, 
Kadian®, Oxycontin®, Duragesic®, and immediate release 
(IR) formulations, such as MSIR, Oxycodone, Hydromor-
phone, Actiq®, etc.
It was suggested that for patients with mild to moderate 
cancer pain opioid analgesic therapy may start with the trial 
of codeine or hydrocodone (Fukshansky et al 2005). Codeine 
is a weak opium alkaloid with a potency 1/10 of morphine. 
Hydrocodone is a more potent hydrogenated ketone de-
rivative of codeine, which is typically available only as a 
combination product with acetaminophen (Vicodin, Norco) 
or ibuprofen (Reprexain, Vicoprofen). Although both these 
drugs are very well suited for the treatment of different mild 
to moderate pain syndromes, they have almost no role in the 
treatment of severe chronic cancer pain. 
Morphine is considered the standard opiate and the drug 
of ﬁ  rst choice in the treatment of moderate to severe cancer 
pain (Schug et al 1990; Wilson et al 1997; Benedetti et al 
2000). It should be titrated to maximum tolerability before 
moving on to another opiate such as fentanyl, hydromor-
phone, or oxycodone. Morphine, first identified nearly 
200 years ago, is available in a variety of formulations (ie, 
parenteral, oral, rectal) and the oral form is available in a 
range of preparations, from immediate release to sustained 
release, allowing it to be precisely titrated to the patient’s 
response (Table 2). The oral formulation is recommended 
initially due to its ease of administration and convenience 
of use. A typical regimen consists of a sustained-release 
(SR) preparation given every 8–12 hours with breakthrough 
doses of immediate-release (IR) form given every 3–4 hours 
in between if needed. As a guide, the cumulative as-needed 
doses should not exceed the total dose given as a sustained 
preparation for that interval. Thus, a patient requiring mor-
phine 120 mg SR every 12 hours should receive morphine 
30 mg IR every 3 hours for breakthrough pain. Regimens 
will require frequent adjustments allowing 3–4 days for the 
patient to respond before initiating a change unless toxicity 
is apparent.
One double-blind, multi-centered crossover study com-
pared the efﬁ  cacy, safety, and pharmacokinetics of a novel 
once-daily morphine formulation and a 12-hour SR morphine 
formulation in the treatment of chronic cancer pain (Hagen 
et al 2005). The investigators found that there was no sig-
niﬁ  cant difference between treatments for evaluations of 
overall pain intensity, analgesic efﬁ  cacy, or adverse events. 
However, the once-daily formulation showed less ﬂ  uctua-
tion in plasma morphine concentration to compare with SR 
form, and most patients chose once-daily morphine dosing 
for continuing pain management, as it was providing more 
stable pain control over the day. 
The most common adverse effects of morphine include 
sedation and some degree of cognitive impairment, which 
usually improves with time in patients taking stable and 
moderate doses of opioid (Bruera et al 1989; Chapman et al 
2002). Nausea and vomiting are frequently seen upon ini-
tiation of therapy and after large dose increases, but usually 
subside with time. Constipation is seen with chronic therapy; 
patients do not develop tolerance to it and typically require 
preemptive treatment with laxatives. 
One of the important aspects to consider for adequate 
opioid treatment is that patients may have varying responses 
to an individual opioid based on various pharmacodynamic 
and pharmacokinetic interactions. For example, morphine 
is hepatically glucuronidated to two metabolites: morphine-
3-glucuronide (M3G) and morphine-6-glucuronide (M6G). 
M3G has no analgesic properties but may be involved in 
certain side effects such as myoclonus. M6G is a more potent 
analgesic than the parent compound and passes much more 
readily into the central nervous system. Morphine and its 
metabolites are excreted by the kidneys and toxicity can be 
seen in patients with underlying renal insufﬁ  ciency or failure. 
In cirrhosis, the bioavailability of morphine is increased due 
to the lack of ﬁ  rst pass metabolism; however, the production 
of the more potent M6G metabolite may decrease result-
ing in a less than optimal analgesic effect. In addition, it 
should be noted that older individuals, who make the vast 
majority of terminal cancer patients, may have an increased 
sensitivity to opioids, due to decreased hepatic metabolism 
and decreased renal excretion, as well as a reduced number 
of opioid receptors due to brain atrophy (Balducci 2003). 
Therefore, it is vital to incorporate interpatient differences 
into the dosing scheme in order to arrive at a tolerable but 
effective regimen.
The effects of active morphine metabolites can be 
induced or inhibited by a variety of medications. The 
anti-epileptic drugs carbamazepine, phenobarbital, 
and phenytoin, as well as the antibiotic rifampin can 
accelerate clearance of morphine. Phenothiazines, 
tricyclic antidepressants, and cimetidine will interfere 
with morphine metabolism and may potentate its ef-
fect if administered simultaneously. Co-administration Therapeutics and Clinical Risk Management 2007:3(3) 390
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of morphine and benzodiazepines may produce strong 
synergistic action resulting in sedation, hypotension, and 
sometimes delirium (Donnely et al 2002).  
Should a patient fail morphine therapy, another opiate 
should be instituted and dosed according to its morphine 
equivalency. Initial dosing of the new opioid should be 
25%–50% less than the expected equivalent dose of morphine 
since the patient may not be cross-tolerant to the new agent. 
Cross-tolerance can be seen particularly when changing from 
a more potent to a less potent agent and is a result of variable 
effects of each opioid on the pain receptors. 
Hydromorphone (Dilaudid®) is a water-soluble opioid 
that is several times more potent than morphine allowing 
for smaller doses to be used. It is available in parenteral, 
rectal, subcutaneous, and oral formulations. However, 
hydromorphone can be also administered via epidural and 
intrathecal routes (Fukshansky et al 2005). Hydromorphone 
should be considered particularly for patients on morphine 
who are having side effects of increased confusion or myoc-
lonus (Friedman and Rodgers 2004). When using injectable 
hydromorphone, clinicians must be aware of its potency. Al-
though IV hydromorphone is six to seven times more potent 
than IV morphine (Sarhill et al 2001) it could be 20 times 
more potent than oral morphine. Hydromorphone relieves 
continuous dull pain more effectively than sharp intermittent 
pain, and when mixed with epinephrine it provides superior 
pain relief (Fukshansky et al 2005).
Fentanyl is a quick acting lipophilic opiate available 
in parenteral, transmucosal, and transdermal formulations. 
Intravenous fentanyl is 70 to 100 times more potent than 
IV morphine (Pereira et al 2001) and has very rapid onset 
of action – 5 minutes to peak analgesia, versus at least 15 
minutes for IV morphine (Gutstein and Akil 2001). Fentanyl 
is most widely used in palliative medicine in the form of a 
transdermal patch (Duragesic®), which is especially useful 
in those patients who do not have enteral access for analge-
sia or for whom nausea and vomiting limit the ingestion of 
the required dose of opioid. The efﬁ  cacy and tolerability of 
transdermal fentanyl for long-term treatment of cancer pain 
have been extensively studied and very well documented 
(Grond et al 1997; Payne et al 1998; Radbruch et al 2001; 
Kornick et al 2003). 
The release of fentanyl from the transdermal system 
is characterized by two distinct phases following initial 
application: during the first phase, a rapid loading dose 
is absorbed from the contact adhesive, which is followed 
by a plateau phase when fentanyl is released from the 
patch reservoir at a constant rate (Varvel et al 1989). 
Although it may take 12–24 hours for the initial onset 
of action to occur (Korte et al 1996), transdermal route 
eliminates gastrointestinal absorption and subsequently 
first-pass metabolism of fentanyl, which makes possible 
to use lower doses of medication and reduce incident of 
adverse effects (Ahmedzai and Brooks 1997; Donner 
et al 1998). Fentanyl usually is not recommended for chil-
dren under 12 years, due to unknown safety profile at this 
age, and is not suitable for patients with severe cachexia 
due to limited subcutaneous fat stores. One of the main 
drawbacks of transdermal fentanyl is that its elimination 
half-life is up to 18 hours after patch removal, thus pa-
tients who experience side effects, especially respiratory 
depression, will need to be monitored and supported for 
a full day following discontinuation. 
The prevalence of breakthrough pain has been well 
described in patients with chronic cancer pain (Portenoy 
and Hagen 1990; Fine and Busch 1998), and IV fen-
tanyl can be successfully used for breakthrough pain 
in the hospital or hospice care. However, for outpatient 
management more convenient choice for breakthrough 
cancer pain will be a rapid-onset opioid Actiq®—the 
oral transmucosal fentanyl citrate (OTFC) lozenge that 
patients can dissolve in the buccal space for immediate 
relief, usually within 5–10 minutes (Farrar et al 1998). 
One study compared its use with oral immediate-release 
morphine and found OTFC to be superior for fast pain 
control (Coluzzi et al 2001). Other study demonstrated 
that OTFC may be an effective alternative to intravenous 
opioids in rapidly titrating analgesia in selected opioid-
tolerant cancer patients who are in pain crisis (Burton 
et al 2004a).
Another centrally acting synthetic opioid, transdermal 
buprenorphine, is now being widely prescribed in Europe 
and Australia for cancer pain management (Budd 2003; Skaer 
2004). Transdermal buprenorphine is contained in a matrix 
patch as opposed to traditional reservoir patch technology 
used for transdermal fentanyl, which makes it more robust in 
handling. In a matrix system, the substance is an integral part 
of the polymer structure of the patch. Thus, while damaging 
a reservoir patch might result in ‘dose dumping’ and poten-
tially overdosing the patient, damaging a matrix patch will 
not interfere with the controlled release of the medication 
(Evans and Easthope 2003).
Oxycodone is a synthetic opioid that is metabolized 
hepatically to the active oxymorphone. One study compared 
controlled-release oxycodone and morphine tablets in 45 
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drugs have provided similar analgesic effects, there were 
differences in pain relief in those patients who had underly-
ing renal or hepatic dysfunction with better pain control in 
patients receiving oxycodone (Heiskanen et al 2000). This 
may be due to the accumulation of active metabolites or 
differences in the phenotype for CYP2D6 that metabolizes 
oxycodone. This study stresses the importance of pharma-
cogenomics in guiding and individualizing pain therapy 
in the future. In most markets, oxycodone is signiﬁ  cantly 
more expensive than morphine and is thus less attractive 
as a ﬁ  rst-line analgesic (Friedman and Rodgers 2004). CR 
oxycodone (Oxycontin®), based on special drug delivery 
system known as AcroContin system, uses a dual-control 
matrix with two hydrophobic polymers, which are not 
inﬂ  uenced by pH and therefore are independent of acidity. 
Oxycontin® is effective in moderate to severe cancer pain 
and allows for convenience of every 12 hours administra-
tion (Fukshansky et al 2005).  
Methadone is an inexpensive synthetic opioid agonist 
that has a very long half-life, no active metabolites, and 
little tendency to induce tolerance in patients. It has unique 
properties that make it useful in treating pain which is poorly 
controlled by other opioids. In addition to binding to the 
opioid µ-receptor, methadone produces analgesic effects 
through its antagonism at the NMDA receptor site and by 
increasing the availability of neurotransmitters serotonin and 
norepinephrine within the central nervous system (Davis and 
Walsh 2001). Methadone works particularly well in opioid 
rotation and may be an effective alternative for cancer pa-
tients, although its equianalgesic dosing to morphine has not 
been ﬁ  rmly established and can vary widely depending on the 
cumulative dose of morphine (Lawlor et al 1998; Ripamonti 
et al 1998; Berland 2000). It occurs more frequently in 
patients previously exposed to high doses of opioids than in 
patients receiving low dose (Fukshansky et al 2005). Metha-
done is available for oral, sublingual, rectal, intravenous, and 
subcutaneous administration, and has relatively low risk for 
opioid-associated adverse effects.
Another potent opioid with simultaneous action at NMDA 
receptor site, levorphanol, can be also considered for treat-
ment of cancer-associated pain in some patients. Its main 
compound dextromethorphan has been shown to be beneﬁ  -
cial for adequate analgesia after bone-malignancy resection, 
especially when used for epidural infusion (Weinbroum et al 
2004). However, earlier reports have provided controversial 
data and showed low efﬁ  cacy of dextromethorphan in con-
trolling cancer associated pain compared with more tradi-
tional opioids, such as morphine (Mercadante et al 1998).
Ketamine also has effects in blocking the NMDA 
receptors and has found some success in treating neuro-
pathic pain, especially in a situation where large doses 
of opioids have contributed to the development of severe 
hyperalgesia (Kannan et al 2002; Hocking and Cousins 
2003). Ketamine can be given by multiple routes: IV, 
IM, SC, oral, rectal, nasal, transdermal, epidural, or even 
intrathecal, although the optimal route of administration 
remains unclear due to a lack of good clinical trials and 
limited experimental studies. Ketamine has been used in a 
variety of neuropathic pain syndromes that are refractory 
to high-dose opioids, such as central pain, ischemic pain, 
and pain associated with posttraumatic nerve or spinal cord 
injury, as well as in ﬁ  bromyalgia, refractory facial pain, 
and post-herpetic neuralgia (Hocking and Cousins 2003). 
However, there is very limited data on ketamine trials in 
cancer pain management. In addition, apart from a few cases 
of complete resolution, ketamine generally did not provide 
a long-term solution in clinical trials for chronic pain, and 
the magnitude of reported beneﬁ  t was often only a little 
more than a placebo effect (Hocking and Cousins 2003). 
Nevertheless, ketamine may be still used in refractory 
cancer pain management as an adjunctive modality for its 
opioid-sparing beneﬁ  ts, allowing smaller doses of morphine 
to be given (Mercadante et al 2000). Limiting its use are 
also the side effects that include sedation, delirium, and 
hallucinations at higher doses.
There are many other opioids available on the market 
today. However, they are not usually recommended for 
routine use in cancer pain management. These include 
diamorphine (commonly known as heroin), meperidine, 
propoxyphene, and mixed agonist-antagonist agents (ie, 
butorphanol, pentazocine, nalbuphine). Heroin is not used in 
the United States in medical practice and considered as one 
of the most dangerous street drugs; however, it is still widely 
used in UK for chronic malignant and nonmalignant pain 
control. Meperidine is metabolized to a neurotoxic metabolite 
normeperidine which can induce seizures if accumulated. The 
effect of propoxyphene can be considered more euphoric than 
analgesic. The mixed agents have a ceiling effect as well as 
the potential in reversing analgesic effects of any pre-existing 
opioid the patient is already taking and, therefore, they are 
not considered efﬁ  cacious.
Although cancer pain usually can be relieved in more 
than 70% of patients using a simple opioid-based regimen, 
there will be always patients who experience little or no pain 
relief despite substantial analgesic doses of opiates or who 
develop intolerable adverse effects. As it was mentioned Therapeutics and Clinical Risk Management 2007:3(3) 392
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earlier, unsatisfactory analgesic response may be due to a 
variety of factors: differences in patient metabolism, multiple 
pain mechanisms, disease progression, and sensitivity to side 
effects. Some nonanalgesic medications are found to be very 
helpful in amplifying the effect of many analgesic drugs, 
particularly in patients with neuropathic pain. In such cases, 
a variety of strategies can be implemented to improve the 
pain control and balance between analgesia and side effects 
(Vielhaber and Portenoy 2002). Among these strategies is the 
use of adjuvant analgesics, although very few of these drugs 
have been actually studied in cancer populations. 
The term “adjuvant analgesic” describes any drug with 
a primary indication other than pain, but with analgesic 
properties in some painful conditions. They can be added to 
the regimen at any time depending on the quality of the pain. In 
some cases, the type of pain suggests the value of one category 
of adjuvant analgesic over another; in others, the existence of 
another symptom concurrent with pain favors the use of a spe-
ciﬁ  c drug (Lussier et al 2004). There are several major groups 
of adjuvant analgesics (ie, antidepressants, antiepileptic drugs, 
muscle relaxants, corticosteroids, etc) that are used nowadays 
to intensify the effect of opioids and NSAIDs on long-term 
pain control. For example, pain that is neuropathic in nature 
is typically not amenable to standard opiate therapy, and the 
addition of tricyclic antidepressants (TCA) or/and antiepileptic 
drugs (AED) can offer a very effective treatment strategy in 
such patients (Collins et al 2000).
TCA such as amitriptyline, imipramine, doxepin, and 
clomipramine are attractive adjuvant agents in cancer 
patients due to their positive effects on mood and sleep. 
The analgesic properties of TCA have been extensively 
studied in a variety of chronic nonmalignant pain condi-
tions (Onghena and van Houdenhove 1992; Watson 2000). 
Although only few clinical trials have specifically evalu-
ated these drugs for cancer pain (Walsh 1986; Magni 
et al 1987), our experience supports their analgesic ef-
fects. Early use of antidepressants is also justified when 
pain is accompanied by depression, which is fairly com-
mon in patients with advanced cancer. However, the use 
of TCA, especially in medically ill or elderly patients may 
be limited due to frequent side effects similar to those 
seen with opiates, which include drowsiness, constipation, 
urinary retention, and dry mouth, as well as such serious 
adverse effects as orthostatic hypotension, liver function 
impairment and cardiotoxicity (Glassman and Bigger 
1981; Pharo and Zhou 2005). TCA are contraindicated 
in patients with a known history of glaucoma and should 
be avoided in patients who are suicidal.
Nontricyclic compounds, such as selective serotonin 
reuptake inhibitors (SSRI) and serotonin-norepinephrine 
reuptake inhibitors (SNRI), are generally safer, have fewer 
side effects than TCA and, therefore, may be considered for 
patients who have relative contraindications to tricyclics or 
have experienced severe adverse effects during the treatment 
(Masand and Gupta 1999). However, there are only limited 
data supporting the analgesic efﬁ  cacy in nonmalignant pain 
management of few SSRI, ie, paroxetine (Sindrup et al 
1990) and citalopram (Sindrup et al 1992), and SNRI, ie, 
venlafaxine (Sindrup et al 2003) and duoxetine (Arnold 
et al 2004), and no studies have been reported on cancer pain 
(Saarto and Wiffen 2005). It is thought that norepinephrine 
reuptake is necessary for an antidepressant to be effective 
on neuropathic pain, therefore, TCA and SNRI in general 
may have better results on alleviating neuopathic pain than 
SSRI (Lynch 2001).
It should be noted that the secondary amines, desipramine 
and nortriptyline, are less anticholinergic, usually better tol-
erated than the tertiary amines, and may be more desirable 
in the elderly (Lussier et al 2004; Maizels and McCarberg 
2005). Another nontricyclic antidepressant, trazadone, has 
been shown to have same effectiveness in cancer-related 
neuropathic pain as amitriptyline (Carr et al 2004).
There is good evidence that AED are particularly useful as 
adjuvant therapy in the long-term management of neuropathic 
pain (Rowbotham et al 1998; Backonja 2000; Tremont-
Lukats et al 2000; Rice and Maton 2001; Jensen 2002). Of 
the all AED, gabapentin (Neurontin) is probably the most 
widely prescribed medication for the treatment of cancer-
related neuropathic pain (Caraceni et al 1999; Oneschuk and 
al-Shahri 2003), although its speciﬁ  c mechanism of action 
has not been fully elucidated at this time. Nonetheless, due 
to its proven analgesic effects, good tolerability, and a rarity 
of drug-drug interactions, gabapentin is now recommended 
as a ﬁ  rst-line agent for the treatment of neuropathic pain of 
diverse etiologies, especially in the medically ill population 
(Dworkin et al 2003a; Caraceni et al 2004). It should be initi-
ated at a daily dose of 100–300 mg and can be increased every 
3 days. The usual maximum dose is 3600 mg daily, but can 
be higher if needed, and an adequate trial should include 1–2 
weeks at the maximum-tolerable dose (Lussier et al 2004). 
Gabapentin is usually well tolerated, and the most common 
side effects are somnolence, dizziness, and unsteadiness, 
which are typically not severe if carefully titrated.
There are several other AED, such as carbamazepine 
(Backonja 2000), phenytoin (Yajnik et al 1992), lamotrigine 
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(Dworkin et al 2003b), and levetiracetam (Price 2004), that 
have been reported to be efﬁ  cacious in alleviating different 
neuropathic pain syndromes, including cancer-related pain 
(Yajnik et al 1992; Dunteman 2005). In general, the last 
three drugs are well-tolerated and lack signiﬁ  cant drug-drug 
interaction, which makes them superior to carbamazepine 
or phenytoin for the long-term management of neuropathic 
pain. The most frequent serious adverse effects of long-term 
therapy with carbamazepine, phenytoin, and lamotrigine are 
bone marrow suppression and liver toxicity, whereas leveti-
racetam only rarely causes pancytopenia, and pregabalin has 
almost no serious adverse effects, except mild thrombocyto-
penia and some congestive heart failure exacerbation.
Corticosteroids belong to another major group of 
medications widely used as an adjuvant therapy for cancer-
related pain syndromes, which include bone pain, neuropathic 
pain from inﬁ  ltration or metastatic compression of neural 
structures, headache due to increased intracranial pressure, 
arthralgias, and pain due to obstruction of hollow viscus 
or distention of an organ capsule (Greenberg et al 1980; 
Ettinger and Portenoy 1988; Watanabe and Bruera 1994; 
Lussier et al 2004). They inhibit prostaglandin production, 
reduce inﬂ  ammation, decrease capillary permeability, and 
have membrane stabilization effects, which reduces neuronal 
excitability (Pharo and Zhou 2005). Corticosteroids can also 
improve appetite, nausea, malaise, and overall quality of life 
(Farr 1990; Mercadante et al 2001). However, it should be 
always taken into consideration that corticosteroids when 
used for a long time can produce signiﬁ  cant adverse effects, 
such as immunosuppression, hypertension, hyperglycemia, 
gastric ulcers, and psychosis; although in cancer patients the 
beneﬁ  t from corticosteroid administration can often outweigh 
the potential risk for adverse effects, particularly in cases of 
central nervous system involvement.
The use of adjuvant medications to treat opiate side 
effects can also allow an increase in the analgesic dose. The 
second-generation (atypical) agent olanzapine (Zyprexa) was 
reported to decrease pain intensity and opioid consumption, 
and improve cognitive function and anxiety, in a recent case 
series of cancer patients (Khojainova et al 2002). Stimulants 
such as methylphenidate or caffeine can increase alertness 
in patients who are experiencing somnolence on a dose of 
morphine that provides sufﬁ  cient pain control (Dalal and 
Melzack 1998). In addition, it has been shown that in cancer 
patients, methylphenidate not only can reduce opioid-induced 
somnolence, but can also signiﬁ  cantly improve cognition, 
treat depression, and alleviate fatigue (Rozans et al 2002). 
Liberal use of laxatives to treat constipation can also allow 
an opioid dose to be escalated. Patients who have pain as-
sociated with bone metastases may especially beneﬁ  t from 
the use of bisphosphonate compounds, such as pamidronate 
or zolendronate (Rosen et al 2001; Seraﬁ  ni 2001; Gordon 
2005). These agents decrease the effect of bone osteoclast 
resorption and are typically given intravenously every 
4 weeks. Calcitonin has also shown some beneﬁ  cial effect 
in alleviating the pain associated with bone metastases (Roth 
and Kolaric 1986; Szanto et al 1992).
Other adjunctive strategies may include topical agents 
(local anesthetics, capsaicin) useful for mucositis or periph-
eral neuropathies (Slavin et al 2004); clonidine, an alpha-2 
adrenergic agonist usually given intraspinally (to avoid 
systemic side effects) for the management of severe intrac-
table cancer pain partly responding to opioids (Eisenach 
et al 1995); amantadine, a noncompetitive NMDA antagonist, 
which has been shown to reduce surgical neuropathic cancer 
pain (Pud et al 1998); baclofen, which can be used in case of 
spasticity and central pain secondary to spinal cord lesions 
(van Hilten et al 2000); benzodiazepines, which used to re-
duce patients’ fear and anxiety related to their disease (Pharo 
and Zhou 2005); as well as antihistamines, antipsychotics, or 
any other unusual adjuvant analgesics, that may be beneﬁ  cial 
for the treatment of severe refractory pain not responsive to 
traditionally used drug combinations.
Surgical management 
of cancer pain
Surgery is rarely used for the treatment of cancer pain 
these days, particularly since longer-acting opioids, such 
as slow-release oxycodone or morphine, and transcutane-
ous fentanyl patches became available. In addition to that, 
prior to considering surgical intervention, one should try a 
variety of less invasive techniques, such as nerve blocks, 
radiofrequency ablations or neurolytic destructions, as well 
as many other procedures available nowadays from the wide 
pain management arsenal.
When it comes to the choice of pain-relieving surgi-
cal procedures, these are usually divided into two broad 
categories: neurodestruction and neuromodulation. Neurode-
structive procedures involve interruption of pain pathways, 
which can be performed anywhere starting at the level of the 
nerve, nerve root, ganglion, spinal cord, thalamus, or the brain 
stem depending on the nature and extent of the pain (Fenster-
maker 1999; Lordon 2002). One of the most commonly used 
procedures in the past was spinal cordotomy that targets the 
spinothalamic tract on the cervical or upper thoracic level and 
results in eliminating pain sensation from the opposite side Therapeutics and Clinical Risk Management 2007:3(3) 394
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of the body (Jones et al 2003). Although safe and effective 
if done on one side only, it may be associated with a very 
high rate of complications if performed bilaterally. Midline 
myelotomy is reserved for patients with severe bilateral or 
visceral pain (Nauta et al 2000); it interrupts a nonspeciﬁ  c 
pain-transmitting pathway located in the vicinity of the cen-
tral canal of the spinal cord. Thalamotomy is usually aimed at 
either nuclei involved in somatosensory perception or more 
anteriorly located centers that relay affective aspects of pain 
(Whittle and Jenkinson 1995). Cingulotomy targets the part 
of the limbic system that appears to modulate painful sensa-
tions and certain psychological aspects of pain experience; it 
is usually reserved for patients with intractable cancer pain 
after failure of antineoplastic and palliative pharmacological 
treatments and when more conservative analgesic procedures 
are not applicable (Wong et al 1997).
Among positive sides of neurodestructive procedures 
are the relative ease of performance and immediate pain 
relief, making these procedures quite attractive to some 
patients suffering from intractable cancer associated pain 
who failed all means of traditional palliative therapy. 
However, the problems associated with destruction of 
the nervous tissue include: the irreversibility of action, 
particularly of the side effects (numbness and weakness 
that come directly as a result or as a complication of de-
structive operation may take very long time to recover), 
inability to test or reliably predict the effect of procedure 
due to individual anatomical and physiological variabil-
ity, relatively short duration of the effect (most neurode-
structive procedures result in 3 months to 1 year pain 
relief, mainly due to the plasticity of the central nervous 
system), and higher risk of complications with bilateral 
procedures. Also, neurodestructive procedures cannot 
be performed in patients with coagulopathies, which are 
developed due to their disease itself or as an unwanted 
side effect of the treatment. Despite all these, carefully 
selected and performed neurodestructive procedures may 
be useful for certain cancer patient populations (Kanpolat 
et al 1995). For example, a patient with gynecological 
malignancy who suffers from unilateral pelvic and leg 
pain due to radiation effect or direct tumor invasion of the 
lumbar plexus and has a life expectancy of 2–3 months, 
may be an excellent candidate for a cervical cordotomy, 
which has a unique chance of rendering the patient pain-
less and free of narcotic medication side effects for the 
rest of her life.
Chronic abdominal pain associated with pancreatic and 
other types of intra-abdominal cancer can be successfully 
treated by celiac plexus block (injection of a neurolytic 
agent near the celiac plexus). Analysis of the available data 
regarding the efﬁ  cacy and safety of this procedure to control 
cancer pain has shown that celiac block provided long-lasting 
beneﬁ  t for 70% to 90% of patients with different types of 
abdominal cancer with mean pain scores decreased by 40% in 
average (Eisenberg et al 1995; Shah et al 2003). Orthostatic 
hypotension, local pain, and diarrhea were some of common 
side-effects of this procedure, but were conservatively man-
aged with prompt resolution of the symptoms. Only a few 
patients had been reported to develop severe neurological 
complications, such as lower extremity weakness and par-
esthesia, from the procedure (Eisenberg et al 1995). In cases 
of visceral and pelvic pain associated with extensive gyneco-
logic, colorectal, or genitourinary cancer, neurolytic block of 
the hypogastric plexus can be used (de Leon-Casasola et al 
1993; Plancarte et al 1997). Although the reported results of 
this procedure in general are less convincing than for celiac 
plexus block (probably due the character of the cancer and 
possible more extensive involvement of bone structures in 
this group of patients), in cases of medically intractable pelvic 
pain, hypogastric block may be still beneﬁ  cial to consider, 
all the more that no serious complications were reported in 
literature related to this procedure. 
In addition, local nerve blocks or neurolysis with phenol 
or alcohol can be used for treating localized pain (Miguel 
2000), and kyphoplasty used for painful vertebral compres-
sion fractures in patients with disseminated metastatic cancer 
(Fourney et al 2003).
Electrical neuromodulation, the electrical stimulation of 
neural structures (peripheral nerves, dorsal columns of spinal 
cord, and brain stimulation), although widely used nowadays 
for successful treatment of intractable neuropathic and central 
pain, has almost no role in the treatment of cancer-related 
pain (Taub 2003). Spinal cord stimulation may be helpful 
for those with primary neuropathic nature of pain, such as 
patients with arachnoiditis, but is unlikely to eliminate the 
signiﬁ  cant nociceptive component of cancer pain. Although 
spinal cord stimulation has been tried in patients after pelvic 
exenteration with severe, intractable pain due to radiation 
necrosis, and showed up to 60% reduction in pain, decrease 
in opioid consumption, and overall improvement in quality 
of life for longer than 3 years (Miguel 2000), this treatment 
modality is not yet considered as one of the recommended 
treatments for intractable cancer pain.
Chemical neuromodulation, on the other hand, has 
become widely accepted in the treatment of cancer pain. 
Intrathecal opioids (such as morphine and hydromorphone) Therapeutics and Clinical Risk Management 2007:3(3) 395
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given alone or in combination with adjuvant medications 
(alpha-adrenergic agonists, eg, clonidine, or local anesthet-
ics, eg, bupivacaine) are now commonly used for medi-
cally intractable cancer pain (Smith et al 2002; Rauck et al 
2003). Although these agents may be delivered via variety 
of catheters and ports, most accepted practice consists of 
the implantation of a self-contained pump that delivers 
medication at a speciﬁ  c rate into the subarachnoid space 
via a dedicated intrathecal catheter (Slavin et al 2002). 
Intrathecal administration of opioids is an option for those 
patients whose effective systemic dose cannot be tolerated 
due to presence of unacceptable side effects or whose pain 
is refractory to conventional therapy. Intrathecal infusion 
bypasses the blood–brain barrier and results in much higher 
cerebrospinal ﬂ  uid concentrations with less medication. 
Compared with the epidural route, intrathecal infusion is 
associated with higher rates of satisfactory pain relief and 
lower rates of treatment failure and technical complications 
(Dews and Mekhail 2004). 
Morphine has been extensively studied intrathecally 
for patients with cancer and found to be more effective 
in relieving nociceptive pain versus neuropathic pain 
(Becker et al 2000). One multicenter, randomized clini-
cal trial demonstrated that patients with refractory cancer 
pain are more effectively treated with addition of implant-
able intrathecal drug delivery system to a comprehensive 
medical management (Smith et al 2002). In this study, the 
patients who received intrathecal morphine infusion had 
significantly better pain relief at four weeks than patients 
treated by conventional medications alone. In addition, 
the toxicity scores representing the cumulative analysis 
of combined side effects from the treatment were reduced 
by 50% in intrathecal pump group. And finally, patients 
with implanted intrathecal drug delivery system had 
significant reduction of fatigue and depressed conscious-
ness, as well as improved rate of survival at six months. 
Several other clinical studies (retrospective, as well as 
prospective, randomized multicenter trials) have shown 
that addition of intrathecal opioid administration through 
programmable drug delivery system can significantly 
increase pain control, reduce toxicities, and improve 
overall survival and quality of life in cancer patients with 
refractory pain (Gilmer-Hill et al 1999; Rauck et al 2003; 
Burton et al 2004b). 
An intrathecal pump can be implanted into the subcutaneous 
fat of the abdomen to provide a continuous infusion of medica-
tions. The older pumps had preset infusion rates (continuous 
ﬂ  ow pumps); therefore each dose adjustment had to be done by 
changing the concentration of the drug inside the pump. More 
commonly used nowadays, programmable pumps contain an 
electronic module that allows adjustment of the drug infusion 
rate using telemetry programming. All pumps have to be reﬁ  lled 
at regular time intervals, but patients usually tolerate these reﬁ  lls 
quite well as they are done every one to three months in ofﬁ  ce 
or clinic settings by simple insertion of the needle into the center 
of the reservoir through the skin. The most common side effects 
of intrathecal opioid therapy are nausea and vomiting, and the 
most frequent complications include infection or hematoma at 
the surgical site. 
Other drugs that can be administered intrathecally in-
clude hydromorphone, bupivacaine, clonidine, baclofen, and 
ziconotide (Kedlaya et al 2002). Hydromorphone is one of 
the ﬁ  rst alternatives to consider for intrathecal administration 
when morphine therapy becomes not suitable for any reason. 
Fentanyl has been also tried intrathecally, however, due to low 
solubility in cerebrospinal ﬂ  uid it does not dissipate far from 
the site of injection, therefore is not widely used for cancer 
pain treatment (Lordon 2002). 
Clonidine and bupivacaine are the most commonly 
used nonopioid medications for intrathecal administration 
in cancer patients. They are both used in combination with 
morphine to amplify its analgesic effect. Clonidine produces 
analgesia by its action on alpha-2 receptors on presynaptic 
primary afferents and postsynaptic dorsal horn neurons of 
the spinal cord, which causes a decrease in the release of 
C-ﬁ  ber neurotransmitters (eg, substance P) and inhibition 
of preganglionic sympathetic transmission (Hassenbusch 
et al 2002). Clonidine can produce marked bradycardia, 
orthostatic hypotension, and sedation at higher doses and 
should be used cautiously.
Local anesthetic bupivacaine produces its analgesic ef-
fect by blocking voltage-sensitive sodium channels and 
thus, preventing the generation and conduction of nerve im-
pulses. Bupivacaine can be very helpful adjunct to morphine, 
particularly in the treatment of neuropathic pain (Mercadante 
1999b; Kedlaya et al 2002). However, its dosing is limited by 
potential neurotoxicity, which can result in numbness, motor 
weakness, and bowel or bladder dysfunction at higher doses. 
Motor block may be seen at doses as low as 10 mg per day, 
but slower dose titration can generally overcome this adverse 
effect. 
GABAB agonist baclofen can be used in cancer pa-
tients with associated sever spasticity and/or dystonia 
(Gatscher et al 2002). When administered intrathecally, 
baclofen inhibits both monosynaptic and postsynaptic 
reflexes at the spinal level and produces muscle relax-Therapeutics and Clinical Risk Management 2007:3(3) 396
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ation. In addition, doses ranging 3–20 µg/hr have been 
shown to be effective in a variety of neuropathic pain 
syndromes through unclear yet mechanism (Hilten et al 
2000). Sedation, hypotonia with weakness, and urinary 
retention are some of the side effects of intrathecal 
baclofen therapy. It has been also reported that abrupt 
discontinuation of intrathecal baclofen, regardless of the 
cause, can be life-threatening, and may result in high fe-
ver, altered mental status, exaggerated rebound spasticity, 
and even rhabdomyolysis, multiple organ-system failure 
and death (Rigoli et al 2004; Kao et al 2003; Mohammed 
and Hussain 2004). 
Several years ago Elan Pharmaceuticals introduced a 
new analgesic drug, ziconotide, which has been recently 
approved by FDA for intrathecal treatment of persistent 
neuropathic pain in the United States. Ziconotide binds to 
specific N-type voltage-sensitive calcium channels found 
in neural tissue and acts by blocking neurotransmitter 
release from primary nociceptive afferents terminating 
in the superficial layers of the dorsal horn of the spinal 
cord (Miljanich and Ramachandran 1995; McGivern and 
McDonough 2004). This mechanism of action distin-
guishes ziconotide from all other analgesics, including 
opioids. In fact, ziconotide is potently antinociceptive in 
animal models in which morphine exhibits poor anti-no-
ciceptive activity (Miljanich 2004). The results from few 
multicenter randomized, double-blind, placebo-controlled 
trials showed that intrathecal ziconotide provided clini-
cally and statistically significant analgesia in patients with 
severe pain from cancer or AIDS (Mathur 2000; Staats 
et al 2004). However, although the safety of ziconotide 
administered as a continuous intrathecal infusion has been 
evaluated in over 1000 patients participating in acute and 
chronic pain clinical trials, lack of long-term prospective 
studies and high incidence of dose-dependent adverse 
effects during the initial titration stage of continuous in-
trathecal infusion of ziconotide currently limit its use as a 
drug of first choice even in patients with advanced cancer 
who fail the traditional methods of pain control (Webster 
et al 2001; Wermeling et al 2003; Doggrell 2004).
Benefits of intrathecal pumps are quite obvious: due to 
drug delivery route, equianalgesic effect may be reached 
at doses about 100 times lower than with systemic admin-
istration, which significantly decreases the dose-related 
side effects of opioid medications; the patient does not 
have to think about constant need to have the oral medica-
tion available (with associated reduction of risks related 
to abuse and mishandling of opioids); continuous drug 
delivery eliminates fluctuations in the drug level that are 
inevitable with bolus oral or parenteral dosing (Slavin 
and Solko 2003). In addition, chemical neuromodulation 
is both adjustable and reversible, so the side effects of 
the treatment may be minimized by either changing the 
rate of infusion or drug composition, or by stopping the 
therapy altogether without any lasting consequences. The 
treatment is also testable; the patient and the caregiver 
may estimate the degree of pain relief from the results of 
a pre-surgical medication trial. 
At the same time, implantable devices are associated with 
higher upfront costs related to the procedure and the device 
itself, potential risk for infection and hardware malfunc-
tion, need for general anesthesia for system implantation, 
and similar procedural contraindications (coagulopathy, 
active systemic infection, etc) as with any other surgical 
intervention. 
Besides adverse effects that are related directly to 
intrathecal administration of medications, there are not 
many serious complications reported for intrathecal drug 
delivery system implantation itself. Some of the common 
complications are infection, including few reports of as-
sociated meningitis, granuloma formation at the tip of the 
subarachnoid catheter, bleeding or hematoma at the site of 
the surgery, and malfunctioning of the device. All hard-
ware-related complications are fully reversible without 
serious consequences and usually easily treated by either 
surgical revision of the implanted drug delivery system 
or complete removal of the device. Another consideration 
that may affect the decision to proceed with permanent 
implantation of intrathecal drug delivery system could 
be the cost of the hardware and related expenses, which 
may be noteworthy. However, several studies showed 
overall cost-saving benefit of this modality versus, for 
example, externalized epidural catheter in the treatment of 
intractable cancer pain when patients have estimated life 
expectancy of at least 3 to 4 months (Bedder et al 1991; 
Erdine and Talu 1998; Miguel 2000). Therefore, hard-to-
control cancer pain in patients with more than 3 months 
survival is a well-founded indication for intrathecal drug 
delivery pump implantation when all conventional medi-
cal treatment regimens fail. 
Summary
Because of the negative consequences on both patients 
and their families, and wide variety of pain management 
techniques available nowadays, patients with cancer should 
be comforted with maximally achievable pain control and Therapeutics and Clinical Risk Management 2007:3(3) 397
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not live in fear of inadequately treated pain. As the survival 
of patients with cancer becomes longer, reliable pain relief 
is now a high-priority issue that warrants both scientiﬁ  c 
research and industrial development of new devices and 
pharmaceutical agents that would make this pain relief 
complete, safe, and lasting. 
Therefore, current approach to pain control should be 
individualized for every patient and will require knowledge 
of the cancer type, the drugs available on the market, the 
patients’ metabolism, drug tolerances, and even their genetic 
morphology. Periodical re-evaluation of patient’s medica-
tion regimen is essential to ﬁ  nely tune their analgesia and 
to minimize the exposure to potentially dangerous adverse 
effects. In addition, the approach must be interdisciplinary 
in nature: a surgeon, oncologist, pain specialist, pharmacist, 
psychologist, or physical therapist cannot treat the cancer 
pain alone; only by working together can these specialists 
give the cancer patient relief from the most fearsome symp-
tom of their disease—their persistent pain.
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